Clinical trials: Injector
Achondroplasia
Bioequivalence Study to Compare Two Injection Devices for BMN 111 in Healthy Participants
The purpose of this study is to establish the bioequivalence of a single SC dose of BMN 111 administered using a vial and syringe versus using an injector pen.
- Trial name
- NCT05813314
- Testing
- BMN 111 administration via Injector Pen, BMN 111 administration via vial and syringe
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- BioMarin Pharmaceutical
Healthy Volunteers
A Study to Evaluate the Bioavailability of Teduglutide Administered Subcutaneously by Syringe Injection Versus Pen Injector in Healthy Adult Participants
The purpose of this study is to evaluate the bioavailability of teduglutide administered as a single subcutaneous (SC) fixed dose (depending upon participant weightband assignment) delivered by a syringe injection and the same…
- Trial name
- NCT04465396
- Testing
- Teduglutide, Syringe Injection, Pen injector
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Shire
Healthy
A Study to Learn How Different Injector Pens Affect the Study Medicine Called Genotropin (Somatropin) Delivery and Taken up Into the Blood in Healthy Adults
The purpose of this clinical study is to learn about how different injector pens affect: how the study medicine (called Genotropin) is delivered into the body and how the study medicine is taken up into the blood in healthy…
- Trial name
- NCT07542886
- Testing
- Marketed Genotropin Pen 12, New Genotropin Injector Pen, Genotropin 4mg
- Where
- Belgium
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Pfizer
Geographic Atrophy Secondary to Age-related Macular Degeneration
A Study to Evaluate KRIYA-825 (VV-14295) in Adults With Geographic Atrophy Secondary to Age-related Macular Degeneration
The goal of this study is to evaluate how safe and tolerable KRIYA-825 (VV-14295) is and to determine how effective it is in reducing the growth of geographic atrophy (GA) lesions in the treated eye in patients with GA secondary…
- Trial name
- VISION (NCT06765980)
- Testing
- VV-14295
- Where
- 4 sites in United States, Canada and 2 more
- Volunteers
- 62 people
- Sponsor
- Kriya Therapeutics, Inc.
Primary Open-angle Glaucoma
Multicenter Study Using Glaukos® Trabecular Micro-Bypass Stent Model GTS400 Using the G2-M-IS Injector System in Conjunction With Cataract Surgery
Evaluate the safety and efficacy of the Glaukos Trabecular Micro-Bypass Stent Model GTS400 using the G2-M-IS injector system in conjunction with cataract surgery vs.
- Trial name
- NCT01461291
- Testing
- iStent inject, Cataract surgery
- Where
- United States
- Volunteers
- 505 people
- Sponsor
- Glaukos Corporation
Healthy Volunteers
Study to Access the Relative Bioavailability of Subcutaneous Dose of Nemolizumab When Administered Via Auto-Injector Versus Dual-Chamber Syringe
This study was to compare the rate and extent of absorption of a single dose of nemolizumab administered with auto-injectors [AI] (test) versus dual-chamber syringes [DCS] (reference) under controlled conditions in healthy adult…
- Trial name
- NCT05405985
- Testing
- Nemolizumab
- Where
- 2 sites in United States
- Volunteers
- 192 people, healthy volunteers welcome
- Sponsor
- Galderma R&D
Breast Augmentation
Mia® Clinical Study
This study will follow 100 women over 36 months (3 years) to evaluate how safe and effective a minimally invasive breast augmentation procedure is.
- Trial name
- NCT06792409
- Testing
- Minimally invasive breast augmentation procedure with a trans-axillary approach.
- Where
- Costa Rica
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Establishment Labs
Rheumatoid Arthritis
A Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Active Rheumatoid Arthritis
Clinical trial to evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Active Rheumatoid Arthritis
- Trial name
- NCT04171414
- Testing
- CT-P17 SC AI (adalimumab)
- Where
- Poland
- Volunteers
- 62 people
- Sponsor
- Celltrion
Healthy Volunteers (Diabetes Mellitus, Type 2)
A Clinical Trial Looking at the Comparability of 2 Different Forms of Semaglutide
In this trial, two approved solutions of the medicine semaglutide will be compared in healthy volunteers. The purpose of this trial is to see if semaglutide B and semaglutide D solutions are comparable with regards to moving…
- Trial name
- NCT05232708
- Testing
- Semaglutide B, 1.34 mg/mL, Semaglutide D, 1.0 mg/mL
- Where
- United Kingdom
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Healthy Study Participants
A Bioequivalence Study of Bimekizumab Given as 1x2mL or 2x1mL Subcutaneous Injection Using an Autoinjector in Healthy Study Participants
The purpose of the study is to compare the pharmacokinetics (PK), safety and tolerability of a single subcutaneous (sc) dose of bimekizumab (BKZ) when administered using bimekizumab-autoinjector (AI)-2mL presentation versus…
- Trial name
- NCT05292131
- Testing
- bimekizumab
- Where
- 2 sites in United States, Germany
- Volunteers
- 121 people, healthy volunteers welcome
- Sponsor
- UCB Biopharma SRL
Healthy Subjects
A Comparative Study of Selatogrel (ACT-246475) Formulations in Healthy Subjects
The main purpose is to study the pharmacokinetics of selatogrel (ACT-246475) using different administration modes and formulations.
- Trial name
- NCT04557280
- Testing
- Selatogrel
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Viatris Innovation GmbH
Overweight, Obesity
A Research Study to Compare Two Different Forms of Once-weekly Semaglutide in Two Different Injection Pens
The study will look at how 2 different semaglutide versions reach and stay in the blood after injection. The study aims to show similar levels of semaglutide in the blood when using the different semaglutide versions.
- Trial name
- NCT04238962
- Testing
- Semaglutide (administered by DV3396 pen-injector), Semaglutide (administered by PDS290 pen-injector)
- Where
- Germany
- Volunteers
- 111 people
- Sponsor
- Novo Nordisk A/S
Metabolism and Nutrition Disorder, Obesity
Investigating Bioequivalence Between Single-dose Liraglutide Administered Subcutaneously With Two Different Pen-injectors
This trial is conducted in Europe. The aim of this trial is to investigate bioequivalence between single-dose liraglutide administered subcutaneously with two different pen-injectors.
- Trial name
- NCT02207348
- Testing
- liraglutide
- Where
- Germany
- Volunteers
- 24 people
- Sponsor
- Novo Nordisk A/S
Healthy Volunteers, Diabetes Mellitus, Type 2
A Research Study Looking at Similarity Between Once-weekly Semaglutide Versions for Different Injection Pens
The study will look at how two different semaglutide versions reach and stay in the blood after injection. The study aims to show similar levels of semaglutide in the blood when using the different semaglutide versions.
- Trial name
- NCT04152915
- Testing
- Semaglutide
- Where
- Germany
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Systemic Lupus Erythematosus
Single Dose Study to Investigate the Pharmacokinetics (PK) and Safety of Belimumab 200 Milligrams (mg) Intravenous and 200 mg Subcutaneous Via Auto-injector in Chinese Healthy Subjects
This is an open-label, randomized, parallel group, single dose study in healthy Chinese subjects. The purpose of this study is to characterize the pharmacokinetic profile and safety profile of 200 mg single dose of belimumab…
- Trial name
- NCT04136145
- Testing
- Belimumab for IV, Belimumab for SC
- Where
- China
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Seizures, Epilepsies, Partial
Efficacy and Safety of Diazepam in the Management of Refractory Epilepsy in Selected Patients Who Require Intermittent Medical Intervention for Acute Repetitive Seizures.
To evaluate the efficacy and safety of diazepam in the management of refractory epilepsy in selected patients who require intermittent medical intervention for the control of episodes of acute repetitive seizures.
- Conditions
- Seizures, Epilepsies, Partial, Epilepsy, Complex Partial, Epilepsy, Generalized
- Trial name
- NCT00319501
- Testing
- Vanquix Auto-Injector (Diazepam Injection)
- Where
- 86 sites in United States
- Volunteers
- 234 people
- Sponsor
- Pfizer
Febrile Neutropenia
A Comparative Evaluation of Pharmacokinetics and Immunogenicity.
The Goal of these study is to evaluate and To compare the pharmacokinetics (PK) of the Test product (T) getting administered through prefilled syringe with on-body injector with Reference product as prefilled syringe following a…
- Trial name
- NCT06918587
- Testing
- TPI-120 with On body injector, Fylntera
- Where
- Jordan
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Kashiv BioSciences, LLC
Sjögrens Disease, Systemic Lupus Erythematosus
Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL PFS with1mL Pre-filled Syringe in Adult Participants With Autoimmune Disease
The purpose of this study is to demonstrate the comparability of ianalumab exposure following the sub-cutaneous (s.c.) administration of one injection of 300 mg/2 mL auto-injector (AI) versus two injections of 150 mg/1 mL…
- Conditions
- Sjögrens Disease, Systemic Lupus Erythematosus, Rheumatoid Arthritis
- Trial name
- NCT06293365
- Testing
- VAY736 1ml PFS, VAY736 2 ml PFS, VAY736 2ml AI
- Where
- 37 sites in United States, Argentina and 6 more
- Volunteers
- 155 people
- Sponsor
- Novartis Pharmaceuticals
Healthy Study Participants
A Study to Evaluate the Bioequivalence of Bimekizumab Given as 1x2mL or 2x1mL Subcutaneous Injection in Healthy Study Participants
The purpose of the study is to compare the pharmacokinetics (PK) of bimekizumab when administered subcutaneously (sc) as 1x2 mL versus 2x1 mL, using a bimekizumab-safety syringe presentation or bimekizumab-auto-injector…
- Trial name
- NCT04255862
- Testing
- Bimekizumab
- Where
- Germany
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- UCB Biopharma SRL
Primary Hypercholesterolaemia and Mixed Dyslipidaemia, Atherosclerotic Cardiovascular Disease
Non-interventional Study on the Monthly Administration of 300 mg AliRocumab (PRALUENT®) With the 2 ml SYDNEY Auto-injector
Primary objectives: To assess the effectiveness of the PRALUENT® 2 ml SYDNEY auto-injector as measured by the lipid-lowering effect of alirocumab after approx.
- Trial name
- MARS (NCT05129241)
- Where
- Germany
- Volunteers
- 163 people
- Sponsor
- Sanofi